Ackman, Valeant pursuing Allergan

Ackman's pursuit of Allergan
Ackman's pursuit of Allergan

Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are teaming up to pursue a takeover of Allergan. Allergan shares rose 13 percent on the news.

Valeant, in a filing with the Securities and Exchange Commission, said it expected to offer a mix of stock and about $15 billion in cash for the Botox maker.

Barclays and RBC are lined up to finance the cash portion. Sources told CNBC the deal's total value would be slightly more than $45 billion.

Allergan declined to comment. Click here to see what Allergan's shares are doing now.

Dow Jones first reported the news Monday afternoon.

Read More

Pershing Square, which declined to comment, holds a nearly 10 percent stake in Allergan. The pharma company is best-known for its cosmetology blockbuster Botox.

The SEC filing indicated that Ackman and Valeant agreed in late February to pursue Allergan. Ackman also agreed to hold at least $1.5 billion worth of Valeant shares for one year after the closing of an Allergan merger.

Valeant has been a serial acquirer, recently gobbling up eye care company Bausch + Lomb for $8.7 billion. Earlier last year it bought Obagi Medical Products, a maker of skin-care products. Those are two areas in which Allergan overlaps; the company has a big presence in both ophthalmology and dermatology.

Its acquisition strategy has served it well: Valeant's shares are up 67 percent in the last 12 months, topping performances from even high-flying biotechs like Gilead Sciences and Biogen Idec. Allergan is up 25 percent in that time.

Valeant Chief Executive Officer Mike Pearson has called research and development a risky business, preferring to build the company through acquisitions and partnerships and often cutting jobs and research spending after doing deals.

A former consultant at McKinsey, Pearson has said it is his goal to become one of the world's five biggest drugmakers by 2016, meaning the company would need to reach a market value of $150 billion. Its market cap as of close of trading Monday was about $41 billion.

—With reporting by CNBC's David Faber, Scott Wapner and Meg Tirrell